“Objective: To review primary hyperparathyroidism and the


“Objective: To review primary hyperparathyroidism and the key issues that are relevant to the practicing endocrinologist.

Methods: The latest information on the presentation, diagnosis, and traditional and nontraditional aspects of primary hyperparathyroidism is reviewed.

Results: The diagnosis of primary learn more hyperparathyroidism is straightforward when the traditional hypercalcemic patient is documented to have an elevated parathyroid

hormone (PTH) level. Commonly, patients are identified who have normal serum calcium levels but elevated PTH levels in whom no secondary causes for hyperparathyroidism can be confirmed. Traditional target organs of primary hyperparathyroidism the skeleton and the kidneys continue to be a focus in the patient evaluation. Bone mineral density shows a typical pattern of involvement with the Mizoribine research buy distal one-third radius being selectively reduced compared with the lumbar spine in which bone mineral density is generally well

maintained. Neurocognitive and cardiovascular aspects of primary hyperparathyroidism, while a focus of recent interest, have not been shown to definitively aid in the decision for or against surgery. The recommendation for surgery in primary hyperparathyroidism is based on guidelines that focus on the serum calcium level, renal function, bone mineral density, and age. In patients who do not meet guidelines, a nonsurgical

management approach has merit.

Conclusions: Primary hyperparathyroidism is continuing to show changes in its clinical profile, with normocalcemic primary hyperparathyroidism being a topic of great interest. Skeletal and renal features of primary hyperparathyroidism drive, in most cases, the decision to recommend surgery. In patients who do not meet any criteria for surgery, a conservative approach with appropriate www.selleckchem.com/products/chir-99021-ct99021-hcl.html monitoring is acceptable. (Endocr Pract. 2012;18:781-790)”
“Despite aggressive immunosuppressive therapy, pediatric orthotopic heart transplant (OHT) candidates with elevated pre-transplant panel reactive antibody (PRA) carry an increased risk of rejection and early graft failure following transplantation. This study has aimed to more specifically evaluate the outcomes of transplant candidates stratified by PRA values. Records of pediatric patients listed for OHT between April 2004 and July 2008 were reviewed (n = 101). Survival analysis was performed comparing patients with PRA < 25 to those with PRA > 25, as well as patients with PRA < 80 and PRA > 80. Patients with PRA > 25 had decreased survival compared with those with PRA < 25 after listing (P = 0.004). There was an even greater difference in survival between patients with PRA > 80 and those with PRA < 80 (P = 0.002).

Comments are closed.